Logo image of EYEN

EYENOVIA INC (EYEN) Stock Fundamental Analysis

NASDAQ:EYEN - Nasdaq - US30234E1047 - Common Stock

0.06  0 (-4.15%)

Premarket: 0.0588 0 (-2%)

Fundamental Rating

1

EYEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EYEN have multiple concerns. EYEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EYEN had negative earnings in the past year.
EYEN had a negative operating cash flow in the past year.
In the past 5 years EYEN always reported negative net income.
In the past 5 years EYEN always reported negative operating cash flow.
EYEN Yearly Net Income VS EBIT VS OCF VS FCFEYEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -165.95%, EYEN is doing worse than 87.63% of the companies in the same industry.
EYEN has a worse Return On Equity (-1017.15%) than 84.41% of its industry peers.
Industry RankSector Rank
ROA -165.95%
ROE -1017.15%
ROIC N/A
ROA(3y)-75.11%
ROA(5y)-85.52%
ROE(3y)-175.98%
ROE(5y)-167.48%
ROIC(3y)N/A
ROIC(5y)N/A
EYEN Yearly ROA, ROE, ROICEYEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EYEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EYEN Yearly Profit, Operating, Gross MarginsEYEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200K -400K -600K

More info and screens

0

2. Health

2.1 Basic Checks

EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EYEN has more shares outstanding
The number of shares outstanding for EYEN has been increased compared to 5 years ago.
EYEN has a worse debt/assets ratio than last year.
EYEN Yearly Shares OutstandingEYEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
EYEN Yearly Total Debt VS Total AssetsEYEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

EYEN has an Altman-Z score of -16.09. This is a bad value and indicates that EYEN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EYEN (-16.09) is worse than 82.80% of its industry peers.
EYEN has a Debt/Equity ratio of 0.58. This is a neutral value indicating EYEN is somewhat dependend on debt financing.
EYEN has a worse Debt to Equity ratio (0.58) than 65.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z -16.09
ROIC/WACCN/A
WACC13.3%
EYEN Yearly LT Debt VS Equity VS FCFEYEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

EYEN has a Current Ratio of 0.74. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
EYEN has a worse Current ratio (0.74) than 94.09% of its industry peers.
A Quick Ratio of 0.55 indicates that EYEN may have some problems paying its short term obligations.
The Quick ratio of EYEN (0.55) is worse than 94.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.55
EYEN Yearly Current Assets VS Current LiabilitesEYEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

EYEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.61%.
Measured over the past years, EYEN shows a very negative growth in Revenue. The Revenue has been decreasing by -87.63% on average per year.
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-87.63%
Revenue growth 5YN/A
Sales Q2Q%66.67%

3.2 Future

Based on estimates for the next years, EYEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.73% on average per year.
The Revenue is expected to grow by 168.85% on average over the next years. This is a very strong growth
EPS Next Y9.42%
EPS Next 2Y16.97%
EPS Next 3Y14.6%
EPS Next 5Y15.73%
Revenue Next Year103.02%
Revenue Next 2Y218.92%
Revenue Next 3Y248.29%
Revenue Next 5Y168.85%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EYEN Yearly Revenue VS EstimatesEYEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
EYEN Yearly EPS VS EstimatesEYEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EYEN Price Earnings VS Forward Price EarningsEYEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EYEN Per share dataEYEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

EYEN's earnings are expected to grow with 14.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.97%
EPS Next 3Y14.6%

More info and screens

0

5. Dividend

5.1 Amount

EYEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EYENOVIA INC

NASDAQ:EYEN (1/21/2025, 8:00:02 PM)

Premarket: 0.0588 0 (-2%)

0.06

0 (-4.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners13.6%
Inst Owner Change0%
Ins Owners9.99%
Ins Owner Change0.49%
Market Cap6.69M
Analysts47.5
Price Target2.04 (3300%)
Short Float %4.17%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.07%
Min EPS beat(2)-37.25%
Max EPS beat(2)19.12%
EPS beat(4)1
Avg EPS beat(4)-12.08%
Min EPS beat(4)-37.25%
Max EPS beat(4)19.12%
EPS beat(8)5
Avg EPS beat(8)0.69%
EPS beat(12)6
Avg EPS beat(12)11.7%
EPS beat(16)10
Avg EPS beat(16)12.43%
Revenue beat(2)0
Avg Revenue beat(2)-98.19%
Min Revenue beat(2)-98.79%
Max Revenue beat(2)-97.58%
Revenue beat(4)0
Avg Revenue beat(4)-98.48%
Min Revenue beat(4)-99.52%
Max Revenue beat(4)-97.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-38.46%
PT rev (3m)-81.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)56.93%
EPS NY rev (1m)0%
EPS NY rev (3m)12.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-53.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 209.98
P/FCF N/A
P/OCF N/A
P/B 1.8
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.03
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.95%
ROE -1017.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.11%
ROA(5y)-85.52%
ROE(3y)-175.98%
ROE(5y)-167.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28%
Cap/Sales 970.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.74
Quick Ratio 0.55
Altman-Z -16.09
F-Score3
WACC13.3%
ROIC/WACCN/A
Cap/Depr(3y)460.2%
Cap/Depr(5y)498.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.89%
EPS Next Y9.42%
EPS Next 2Y16.97%
EPS Next 3Y14.6%
EPS Next 5Y15.73%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-87.63%
Revenue growth 5YN/A
Sales Q2Q%66.67%
Revenue Next Year103.02%
Revenue Next 2Y218.92%
Revenue Next 3Y248.29%
Revenue Next 5Y168.85%
EBIT growth 1Y-57.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-157.15%
EBIT Next 3Y50.91%
EBIT Next 5Y40.74%
FCF growth 1Y-15.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.64%
OCF growth 3YN/A
OCF growth 5YN/A